Reports indicated that George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on leave amid internal inquiries. Multiple outlets reported the move and described it as part of growing turbulence within the agency’s leadership. The development has sparked questions about continuity in drug review operations and may complicate high‑stakes regulatory interactions. Stakeholders cited potential impacts on priority reviews and internal morale while urging clarity from the FDA on next steps and interim leadership arrangements.